Stone clinic · KIMS Secunderabad
Medullary Sponge Kidney — Understanding and Managing the Stone-Prone Kidney
Medullary sponge kidney (MSK) is a congenital, non-hereditary structural abnormality of the kidney in which the collecting ducts within the renal medullary pyramids are abnormally dilated, forming tiny cysts or ectatic tubules. These dilated ducts have impaired drainage — urine stagnates within them, creating conditions for calcium crystallisation, stone formation, and infection. MSK is found in approximately 1 in 5,000 to 1 in 20,000 of the general population, but it is present in approximately 12 to 20% of patients with recurrent kidney stones — making it an important diagnosis in the stone recurrence workup.
MSK itself does not directly cause kidney failure or significant reduction in GFR — the condition is structural, not inflammatory, and does not destroy nephrons. What damages the kidneys in MSK is the cascade of secondary complications: recurrent nephrolithiasis (stones forming within the dilated ducts), nephrocalcinosis (calcium deposition), recurrent pyelonephritis (from urinary stasis and stone-related obstruction), and Type 1 distal renal tubular acidosis (which complicates MSK in approximately 30% of cases, dramatically amplifying stone risk). Management of MSK is management of its complications.
How MSK causes kidney stones
The dilated collecting ducts of MSK create multiple simultaneous mechanisms that promote stone formation.
Urinary stasis
Slow urine flow within the dilated ducts allows crystals to nucleate, aggregate, and grow into stones before they are washed out. The ectatic ducts act as a natural stone-trap.
Hypercalciuria
Approximately 60% of MSK patients have hypercalciuria (excess calcium in the urine) — from increased intestinal calcium absorption (absorptive hypercalciuria), or from impaired tubular calcium reabsorption, or from secondary hyperparathyroidism driven by Type 1 RTA-related acidosis mobilising bone calcium.
Hypocitraturia
Low urinary citrate levels, from Type 1 distal RTA in the 30% of MSK patients who have concurrent RTA. Citrate is the most important natural stone inhibitor — its depletion dramatically increases calcium phosphate and mixed stone risk.
Recurrent infection
Stones act as a nidus for bacterial colonisation. Infection-related struvite stones form in the alkaline urine created by urea-splitting bacteria (Proteus, Klebsiella). Struvite stones grow rapidly and may fill the entire collecting system (staghorn calculi).
Clinical presentation and diagnosis
Recurrent kidney stones — the dominant presentation. Often beginning in the 20s or 30s. Calcium oxalate, calcium phosphate, and mixed stones are the most common types in MSK. Many patients have multiple bilateral stones at presentation.
Nephrocalcinosis — calcium deposits within the dilated medullary ducts, visible on plain X-ray as diffuse calcification in the medullary pyramids (a 'bunch of grapes' or 'starfield' appearance), on ultrasound as echogenic medullary pyramids, and on CT as medullary calcifications.
Recurrent UTIs — from urinary stasis and retained stones. Common in women with MSK.
Flank pain — from stone passage or stone-related obstruction.
Haematuria — from stone movement or erosion.
IVU (intravenous urogram) or CT urogram — the diagnostic imaging. The classic IVU finding in MSK: contrast accumulates in the dilated tubules during the excretory phase, producing a 'paintbrush' or 'bouquet of flowers' appearance at the medullary papillae. CT urogram similarly demonstrates medullary tubular ectasia, papillary calcifications, and any stones within the dilated ducts.
Metabolic workup and treatment
24-hour urine collection
The cornerstone of MSK management. Calcium, oxalate, citrate, uric acid, phosphate, sodium, pH, and creatinine. This single investigation identifies all treatable metabolic abnormalities driving stone formation in each patient individually. At KIMS, the metabolic stone clinic performs a systematic 24-hour urine evaluation for every MSK patient.
Type 1 RTA evaluation
Performed for all MSK patients — urine pH above 5.5 despite metabolic acidosis (low serum bicarbonate) confirms concurrent distal RTA. Potassium citrate treatment addresses RTA and simultaneously corrects hypocitraturia.
Hypercalciuria — ~60%
Thiazide diuretics (hydrochlorothiazide — reduces urinary calcium excretion). Dietary sodium restriction (high sodium raises urinary calcium). Normal calcium diet (restricting dietary calcium paradoxically worsens oxalate excretion).
Hypocitraturia (with or without RTA) — ~30–50%
Potassium citrate — raises urinary citrate, corrects acidosis if RTA present, and reduces calcium stone risk substantially.
Hyperuricosuria — ~25%
Allopurinol — reduces uric acid excretion and reduces calcium oxalate stone risk (uric acid crystals act as nuclei for calcium oxalate growth).
Recurrent UTIs and obstruction
Antibiotic treatment based on culture sensitivity · urological management of causative stones.
Obstruction from stones
RIRS or Mini-PCNL for stone clearance — performed by the KIMS urology team after metabolic optimisation
MSK itself is not treatable — the structural ectasia of the collecting ducts is permanent. But the stone-forming metabolic abnormalities — hypercalciuria, hypocitraturia, hyperuricosuria, concurrent RTA — are all treatable. A patient who undergoes metabolic evaluation and targeted treatment at the KIMS stone clinic can dramatically reduce recurrence rates and avoid repeated stone procedures.
Book a Metabolic Stone Clinic Appointment at KIMS for MSK Evaluation
Frequently Asked Questions — Medullary Sponge Kidney
MSK is generally considered non-hereditary — most cases are sporadic. Unlike autosomal dominant polycystic kidney disease (ADPKD), which has a clear Mendelian inheritance pattern, MSK does not follow a predictable familial pattern in the majority of cases. However, a small proportion of MSK cases have been reported in family clusters, and associations with Beckwith-Wiedemann syndrome and hemihypertrophy suggest a genetic component in selected patients. For most patients, MSK is a structural developmental anomaly that occurred during intrauterine kidney development without a hereditary cause.
MSK itself does not cause kidney failure in the vast majority of patients — the structural ectasia of the collecting ducts does not destroy nephrons or cause glomerulosclerosis. Kidney function (creatinine and eGFR) remains normal in most MSK patients throughout their lives. Kidney function may decline in a minority — those with recurrent obstructive episodes from stones causing hydronephrosis and ischaemia, those with recurrent pyelonephritis causing progressive parenchymal scarring, or those with concurrent Type 1 RTA causing progressive nephrocalcinosis and tubular damage. These are secondary complications of MSK — not the primary structural abnormality itself.
MSK and PKD are completely different conditions. MSK affects the collecting ducts within the medullary pyramids — causing tiny ectatic tubules within the inner kidney. Kidney size is normal, GFR is normal, and the condition is non-hereditary. PKD (autosomal dominant) causes progressive enlargement of multiple bilateral cysts throughout the entire kidney — both cortex and medulla — from PKD1 or PKD2 mutations. Kidneys in ADPKD become massively enlarged (sometimes 30 to 40cm) and kidney function declines progressively to ESRD. MSK does not progress to ESRD; ADPKD commonly does. The CT appearances are entirely different.
The dilated collecting ducts of MSK are the anatomical trap that concentrates the effect of all urinary stone risk factors. In a normal kidney, a stone crystal forming in a collecting duct is quickly washed out by urine flow before it can grow to clinical significance. In MSK, the ectatic, poorly draining ducts allow crystals to remain in stagnant urine — giving them time to aggregate and grow. When this structural stasis is combined with metabolic risk factors (hypercalciuria, hypocitraturia, concurrent RTA — all more common in MSK than in the general population), the stone recurrence rate becomes very high.
KIMS Secunderabad — Dr. V. S. Reddy (Senior Consultant Nephrologist), metabolic stone clinic with 24-hour urine collection, RTA evaluation, targeted thiazide and potassium citrate protocols, CT urogram and IVU for MSK diagnosis, urology coordination for RIRS and Mini-PCNL stone clearance. NABH and NABL accredited. Call 040-4488-5000.